Victora Hamamoto News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19 related ARDS - GARDEN will enroll 60 patients hospitalized for COVID19 - First Patient included at University Hospital of Strasbourg Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announces the recruitment of the first patient of its phase 2 GARDEN study to treat COVID-19 related acute respiratory distress syndrome (ARDS) with glenzocimab. GARDEN (clinicaltrials.gov NCT04659109) is a phase 2 study, randomized, double blind, multicenter, placebo controlled, parallel group, exploratory efficacy and safety study of glenzocimab in sars-cov-2-related acute respiratory distress syndrome. GARDEN will enroll 60 patients in France and in Brazil. The Professor Julien POTTECHER, Strasbourg University Hospital, is the Principal Investigator of GARDEN in France. The Professor Victor A. Ham

France generalOswaldo cruzRio grande do sulVictora hamamotoMartine jandrot perrusNewton biocapitalKostenloser wertpapierhandelGilles avenardAnnie florence loyerUniversity hospital of strasbourgSud universityStrasbourg university hospitalPrimer capital armesa foundationUniversity hospitals of strasbourgUniversity hospitalProfessor julien